VIKTORIA-1 Results

In this segment, the experts turn their attention to metastatic HR+/HER2– breast cancer, examining the first results from the VIKTORIA-1 trial evaluating gedatolisib in combination with fulvestrant with or without palbociclib. The discussion explores the unmet need for patients who progress after CDK4/6 inhibitors and the rationale for targeting the PIK3CA wild-type population. The panel reviews the striking progression-free survival gains seen with both the triplet and doublet regimens, along with notable response rates that surpass those of many existing second-line endocrine-based options. They also address key safety considerations—including monitoring for hyperglycemia and overlapping hematologic toxicity—to help pharmacists and care teams anticipate and manage treatment-related risks as these novel combinations move closer to clinical practice.